- Home
- JHG vs NUVL Comparison
JHG vs NUVL Comparison
Compare JHG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHG
- NUVL
- Stock Information
- Founded
- JHG 1934
- NUVL 2017
- Country
- JHG United Kingdom
- NUVL United States
- Employees
- JHG N/A
- NUVL N/A
- Industry
- JHG Investment Managers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- JHG Finance
- NUVL Health Care
- Exchange
- JHG Nasdaq
- NUVL Nasdaq
- Market Cap
- JHG 5.7B
- NUVL 5.6B
- IPO Year
- JHG N/A
- NUVL 2021
- Fundamental
- Price
- JHG $36.64
- NUVL $75.00
- Analyst Decision
- JHG Buy
- NUVL Strong Buy
- Analyst Count
- JHG 11
- NUVL 8
- Target Price
- JHG $41.27
- NUVL $115.50
- AVG Volume (30 Days)
- JHG 1.2M
- NUVL 452.9K
- Earning Date
- JHG 07-31-2025
- NUVL 08-07-2025
- Dividend Yield
- JHG 4.36%
- NUVL N/A
- EPS Growth
- JHG N/A
- NUVL N/A
- EPS
- JHG 2.52
- NUVL N/A
- Revenue
- JHG $2,542,900,000.00
- NUVL N/A
- Revenue This Year
- JHG $3.15
- NUVL N/A
- Revenue Next Year
- JHG $5.84
- NUVL N/A
- P/E Ratio
- JHG $14.56
- NUVL N/A
- Revenue Growth
- JHG 17.85
- NUVL N/A
- 52 Week Low
- JHG $28.26
- NUVL $55.54
- 52 Week High
- JHG $46.68
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- JHG 53.33
- NUVL 48.73
- Support Level
- JHG $36.17
- NUVL $76.42
- Resistance Level
- JHG $37.09
- NUVL $78.94
- Average True Range (ATR)
- JHG 0.63
- NUVL 2.71
- MACD
- JHG -0.07
- NUVL -0.34
- Stochastic Oscillator
- JHG 72.22
- NUVL 31.73
About JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (55% of managed assets), self-directed (22%) and institutional (23%) clients. At the end of March 2025, active equities (58%), fixed-income (24%), multiasset (14%) and alternative (4%) investment platforms constituted the company's $373 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (62%), with customers from Europe, the Middle East, Africa, and Latin America (28%) and the Asia-Pacific region (10%) accounting for the remainder.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.